Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank …
Hard to Treat Diseases and its operating subsidiary Slavica Bio Chem, is providing this brief update to its followers and shareholders. HTDS management continues due diligence with the EU stem cell company and merger discussions.
[Read the full article here]Related News:
Hard to Treat Diseases Inc. Targets an EU Based Stem Cell …
HTDS announces possible merger with EU-based, stem-cell research company
Hard to Treat Diseases Inc. Stem Cell Developments